New drug duo shows promise for tough bladder cancer

NCT ID NCT03854474

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic urothelial carcinoma are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

stage IVb bladder cancer transitional cell carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED UROTHELIAL CARCINOMA METASTATIC UROTHELIAL CARCINOMA STAGE III BLADDER CANCER AJCC V8 STAGE IV BLADDER CANCER AJCC V8

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756, United States
HaysMed

Hays, Kansas, 67601, United States
Lawrence Memorial Hospital

Lawrence, Kansas, 66044, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Mercy Hospital Pittsburg

Pittsburg, Kansas, 66762, United States
Northwestern University

Chicago, Illinois, 60611, United States
Salina Regional Health Center

Salina, Kansas, 67401, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, 06437, United States
Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385, United States
Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105, United States
Smilow Cancer Hospital Care Center-Fairfield

Fairfield, Connecticut, 06824, United States
Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, 06611, United States
Smilow Cancer Hospital-Derby Care Center

Derby, Connecticut, 06418, United States
Smilow Cancer Hospital-Orange Care Center

Orange, Connecticut, 06477, United States
Smilow Cancer Hospital-Torrington Care Center

Torrington, Connecticut, 06790, United States
Smilow Cancer Hospital-Waterbury Care Center

Waterbury, Connecticut, 06708, United States
The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
University Health Truman Medical Center

Kansas City, Missouri, 64108, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116, United States
University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
Yale University

New Haven, Connecticut, 06520, United States
Yale-New Haven Hospital North Haven Medical Center

North Haven, Connecticut, 06473, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.